Effect Of Gastrin And Proglumide On The Cell Of SGC7901Proliferation And Expression Of Reg Ⅳin Human Gastric Cancer

Objectives:1.To study the effects of the different concentrations of pehtagastric(PG)on the growth proliferation of human gastric cancer cells of the SGC7901, and itsreceptor antagonist proglumide (PGL) can block the promoting effect of exogenous andauto-secretion gastric.2. To investigate the changes of the different concentrations ofpehtagastric(PG)、proglumide(PGL) and combining with medication on morphology andthe expression of Reg Ⅳof the line the SGC7901cell.3.To analysis the differentconcentrations of proglumide(PGL) on the rate of cell cycle and cell apoptosis of humangastric cancer cell line of the SGC7901.Methods: Human gastric cancer of the SGC7901cells which are cultured in vitrotake the logarithmic growth phase cells experiment.1. The proliferation inhibition of thePG(10-5、10-6、10-7、10-8mol/L)、PGL（10-2、10-3、10-4、10-5mol/L）and PG(10-7mol/L)combining with PGL（10-2、10-3、10-4、10-5mol/L）to calculate the rate of cell growth inproliferation inhibition rate by measuring the optical density of MTT value(OD);Weobserve drug treatments on cell morphology under inverted optical microscope2. Weanalysis the cell cycle by PI and Flow Cytometry,and analysis cell apoptosis byAnnevinV/FITC-PI.3. We detect the PG(10-7mol/L)、PGL（10-2mol/L）and PG(10-7mol/L)combining with PGL（10-2mol/L）respectively role in the line of the SGC7901gastriccancer cells Reg Ⅳprotein expression by Immunocytochemical (ICC) method.Results:1. Pehtagastric can promote cell proliferation at the concentration of10-5,10-6,10-7mol/L,and comparing with the control group, it has significantdifferentce(P<0.01),10-7mol/L of pehtagastric is the most significant (P<0.001),but it isno difference at10-8mol/L, proglumide can inhibit cell proliferation at the concentrationof10-2、10-3、10-4mol/L,comparing with the control group it has significantdifference (P<0.01), there is no difference at10-5mol/L; Pehtagastric at the concentrationof10-7mol/L combining with proglumide at the concentration of10-2、10-3mol/L can inhibit cellproliferation, combining with proglumide (10-4,10-5mol/L) can promotethe cell proliferation, comparing with the control group are significantly different(P<0.05). Proglumide and combination of the two drugs show that the cell proliferationeffect increase with higher concentration.2. Pehtagastric dose the gastric cancer of SGC7901cell which is lead to the speed ofthe cell proliferation increases and its nucleas become bigger and rounder. A low level ofproglumide treats the SGC7901, it shows mainly through cellular apoptosis morphology, a lowcell adhesion rate and become round shape; A low level of PGL mainly shows morphologicalchanges of necrosis, exfoliated cells increases, a large number of vacuoles necrotic celldebris inside the cell.3. After the different concentrations PGL treatment the SGC7901cells for48hours.PGL at the concentration of10-2、10-3、10-4mol/L all can inhibit the proliferation ofthese cells in S phase.comparing with the control group it has significantdifference (P<0.05).4. Dose the SGC7901cells which are at PG(10-4mol/L), can enhance the expressionof RegIV, PG(10-2mol/L) and the two drugs together can decrease the RegIV expression.Comparing with the negative control group,it has significant difference (P<0.0083);Except PGL group and combination group have no difference (P>0.0083), comparingwith the other group，they all have differences (P<0.0083).Conclusion: In a certain concentration range, Pehta gastric can promote theproliferation of human gastric cancer SGC7901cell, and the cell in RegⅣ proteinexpress increasing.With time and concentration dependent; its receptor antagonist PGLcan block the promoting effect of exogenous and auto-secretion gastric reduceRegⅣ gene expression in gastric cancer cell; gastric may express through the expressionof RegⅣ protein in gastric cancer cells and play an indirect cell proliferation,Reg Ⅳ may be a key down stream genes in the process of gastric cancer development.